Network origin in Sinikka Demaré first degree
Entity | Entity type | Industry | |
---|---|---|---|
Nextech Invest AG
Nextech Invest AG Investment ManagersFinance Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals.
8
| Private Company | Investment Managers | 8 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Sinikka Demaré via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Karolinska Institutet | College/University | Doctorate Degree | |
The Genetics Co., Inc.
The Genetics Co., Inc. Medical/Nursing ServicesHealth Services The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates. | Medical/Nursing Services | Director/Board Member | |
Covagen AG
Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Biotechnology | Chairman | |
SynphaBase AG
SynphaBase AG Miscellaneous Commercial ServicesCommercial Services SynphaBase AG provides contract research and development services to the pharmaceutical and chemical industry. Its products and services include route finding and process development, production of multi-kg up to metric tons, lab scale synthesis and carbohydrates and glycans. The firm’s catalogue includes monosaccharides as building blocks for glycan synthesis with various protecting group patterns and linker systems, disaccharides, oligosaccharides, glycosyl amino acids; core structures and building blocks for carbohydrate-based vaccine. The company was founded by in Arthur Bodenmüller in December 2000 and is headquartered in Pratteln, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
RELAY THERAPEUTICS, INC. | Biotechnology | Founder | |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Biotechnology | Director/Board Member | |
A2 Biotherapeutics, Inc.
A2 Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA. | Miscellaneous Commercial Services | Director/Board Member | |
ARVINAS, INC. | Biotechnology | Director/Board Member | |
University of Anglia Ruskin | College/University | Undergraduate Degree | |
Third Rock Ventures LLC
Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Corporate Officer/Principal | |
Stanford University | College/University | Undergraduate Degree | |
Arrakis Therapeutics, Inc.
Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member | |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
SYROS PHARMACEUTICALS, INC. | Biotechnology | Founder | |
KRONOS BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
IconOVir Bio, Inc.
IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | Biotechnology | Director/Board Member | |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
KINNATE BIOPHARMA INC. | Pharmaceuticals: Major | Director/Board Member | |
TURG POIN | Pharmaceuticals: Major | Director/Board Member | |
BOUNDLESS BIO, INC. | Biotechnology | Director/Board Member | |
AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member | |
Novartis Venture Funds
Novartis Venture Funds Investment ManagersFinance Novartis Venture Funds (NVF) is a venture capital firm with headquarters in Basel, Switzerland and an additional office in Cambridge, MA. The firm was founded in 1996. NVF is a subsidiary of Novartis AG (VX: NOVN) and was created following the 1996 merger of Ciba-Geigy and Sandoz. | Investment Managers | President | |
University of Basel | College/University | Undergraduate Degree | |
Falcon Private Bank AG
Falcon Private Bank AG Investment ManagersFinance Falcon Private Bank AG (Falcon-PB) was previously known as AIG Private Bank Ltd. and was a subsidiary of New York-based American International Group, Inc. until 2009 when they were renamed Falcon upon acquisition by Aabar Investments PJSC (AD: AABAR), an investment company based in Abu Dhabi and majority-owned by the sovereign wealth fund IPIC-International Petroleum Investment Co. Established in 1965, Falcon-PB is based in Zurich with branch and representative offices in Geneva, Dubai, Abu Dhabi, Hong Kong, Singapore and London. Falcon-PB is a wholly-owned subsidiary of Aabar and provides wealth management services for an international clientele of high-net worth private individuals, family offices, asset management firms, private label partners and institutions. They offer personalized and structured private banking solutions, tailored to the individual needs of their clients. | Investment Managers | Chief Investment Officer | |
PineBridge Global Funds - Asia (ex-Japan) Equity Fund
PineBridge Global Funds - Asia (ex-Japan) Equity Fund Investment Trusts/Mutual FundsMiscellaneous AIG South East Asia Fund Plc provided investment services. It was an investment company with variable capital authorized by European Communities Regulations, 2003. The company was founded in July, 1991 and was headquartered in Dublin, Ireland. | Investment Trusts/Mutual Funds | Director/Board Member | |
SANTHERA PHARMACEUTICALS HOLDING AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
PineBridge Global Funds - Greater China Equity Fund
PineBridge Global Funds - Greater China Equity Fund Investment Trusts/Mutual FundsMiscellaneous PineBridge Greater China Equity Fund provided investment services. It was an open-ended investment company with variable capital under the European Communities Regulations, 2003. It was founded in October, 2002 and was headquartered in Dublin, Ireland. | Investment Trusts/Mutual Funds | Director/Board Member | |
PineBridge Global Funds - Asia (ex-Japan) Small Cap Equity Fd.
PineBridge Global Funds - Asia (ex-Japan) Small Cap Equity Fd. Investment Trusts/Mutual FundsMiscellaneous PineBridge Global Funds-Asia ex Japan Small Cap Equity Fund provides investment services. It invests in companies in the ''Asian Region'' countries including Hong Kong, India, Indonesia, Malaysia, Pakistan, China, Philippines, Singapore, Sri Lanka, Taiwan, and Thailand. The company was incorporated on 15th December, 1993 and is headquartered in Dublin, Ireland. | Investment Trusts/Mutual Funds | Director/Board Member | |
PineBridge Global Funds - Asia Dynamic Asset Allocation
PineBridge Global Funds - Asia Dynamic Asset Allocation Investment Trusts/Mutual FundsMiscellaneous PineBridge Global Funds - Asia Balanced Fund provides investment services. It is an investment company with variable capital under the European Communities Regulations, 2003. The fund invests its total assets in a broad range of equity and equity-related securities of Asian companies. It manages and provides investors with income and long-term capital appreciation through investment in equities, equity-related securities and debt securities of Asian issuers in the Asian Region. It was incorporated on 9th June, 1997 and is located in Dublin, Ireland. | Investment Trusts/Mutual Funds | Director/Board Member | |
Hexagon Bio, Inc.
Hexagon Bio, Inc. BiotechnologyHealth Technology Hexagon Bio, Inc. operates as a data-driven biotechnology company. It engages in mining of fungal genome data for drugs. The company was founded by Maureen E. Hillenmeyer, Brian T. Naughton, Colin James Bell Harvey and Yi Tang and is headquartered in Menlo Park, CA. | Biotechnology | Director/Board Member |
Statistics
International
Ireland | 20 |
United States | 17 |
Switzerland | 10 |
United Kingdom | 3 |
Germany | 2 |
Sectoral
Miscellaneous | 19 |
Health Technology | 17 |
Finance | 8 |
Consumer Services | 5 |
Commercial Services | 4 |
Operational
Director/Board Member | 35 |
Private Equity Investor | 4 |
Founder | 3 |
Chief Investment Officer | 3 |
Corporate Officer/Principal | 3 |
Most connected contacts
Insiders | |
---|---|
Thomas Lips | 23 |
Jakob Loven | 19 |
Rudolf Gygax | 9 |
Rocco Sgobbo | 2 |
Roland Ruckstuhl | 1 |
Kristina Beeler-Kakalacheva | 1 |
Wolfram Grüning | 1 |
Marco Weibel | 1 |
- Stock Market
- Insiders
- Sinikka Demaré
- Company connections